W. Howard Robin's most recent trade in Nektar Therapeutics was a trade of 1,500 Common Stock done at an average price of $30.2 . Disclosure was reported to the exchange on Sept. 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 30.16 per share. | 02 Sep 2025 | 1,500 | 67,840 (0%) | 0% | 30.2 | 45,240 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2025 | 86,666 | 86,666 | - | - | Stock Option | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 26.59 per share. | 19 Aug 2025 | 1,573 | 69,340 (0%) | 0% | 26.6 | 41,826 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.67 per share. | 19 May 2025 | 23,208 | 1,063,693 (0%) | 0% | 0.7 | 15,549 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 19 Feb 2025 | 23,774 | 1,086,901 (0%) | 0% | 1.0 | 24,012 | Common Stock |
| Nektar Therapeutics | Robin Howard W. | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.99 per share. | 17 Dec 2024 | 85,035 | 1,110,675 (0%) | 0% | 1.0 | 84,185 | Common Stock |
| Nektar Therapeutics | W. Howard Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 17 Dec 2024 | 46,995 | 1,195,710 (0%) | 0% | 1.0 | 47,465 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 1,300,000 | 1,300,000 | - | - | Stock Option | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 821,250 | 821,250 | - | - | Stock Option | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 410,625 | 1,242,705 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 19 Nov 2024 | 16,278 | 832,080 (0%) | 0% | 1.0 | 16,441 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 1.28 per share. | 19 Aug 2024 | 14,881 | 848,358 (0%) | 0% | 1.3 | 19,048 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 1.75 per share. | 17 May 2024 | 16,650 | 863,239 (0%) | 0% | 1.8 | 29,138 | Common Stock |
| Nektar Therapeutics | Robin W. Howard | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.68 per share. | 20 Feb 2024 | 20,033 | 879,889 (0%) | 0% | 0.7 | 13,622 | Common Stock |
| Nektar Therapeutics | Robin Howard W. | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2023 | 1,300,000 | 1,300,000 | - | - | Stock Option | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 16 Aug 2023 | 19,998 | 919,799 (0%) | 0% | 0.8 | 15,598 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.72 per share. | 16 May 2023 | 20,361 | 939,797 (0%) | 0% | 0.7 | 14,660 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.00 per share. | 16 Feb 2023 | 19,635 | 960,158 (0%) | 0% | 3 | 58,905 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 821,250 | 821,250 | - | - | Common Stock | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 410,625 | 1,031,566 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 4.76 per share. | 15 Aug 2022 | 13,759 | 1,017,807 (0%) | 0% | 4.8 | 65,493 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2022 | 68,450 | 657,470 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.95 per share. | 15 May 2022 | 36,529 | 620,941 (0%) | 0% | 4.0 | 144,290 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 10.95 per share. | 16 Feb 2022 | 12,480 | 589,020 (0%) | 0% | 11.0 | 136,656 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 223,750 | 223,750 | - | - | Stock Option | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 126,050 | 601,500 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 94,100 | 518,223 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 13.16 per share. | 15 Nov 2021 | 42,773 | 475,450 (0%) | 0% | 13.2 | 562,893 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2021 | 167,650 | 167,650 | - | - | Stock Option | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 13.83 per share. | 16 Aug 2021 | 11,515 | 424,123 (0%) | 0% | 13.8 | 159,252 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 18.30 per share. | 17 May 2021 | 11,560 | 435,638 (0%) | 0% | 18.3 | 211,548 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 22.37 per share. | 16 Feb 2021 | 11,495 | 447,198 (0%) | 0% | 22.4 | 257,143 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. | 02 Feb 2021 | 150,000 | 608,693 (0%) | 0% | 8.8 | 1,320,000 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 150,000 | 0 | - | - | Stock Option | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 150,000 | 75,000 | - | - | Stock Option | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. | 02 Feb 2021 | 150,000 | 608,693 (0%) | 0% | 8.8 | 1,320,000 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 19.72 per share. | 02 Feb 2021 | 150,000 | 458,693 (0%) | 0% | 19.7 | 2,958,000 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 19.69 per share. | 02 Feb 2021 | 139,500 | 469,193 (0%) | 0% | 19.7 | 2,746,755 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.10 per share. | 02 Feb 2021 | 91,863 | 516,830 (0%) | 0% | 20.1 | 1,846,446 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 75,000 | 150,000 | - | - | Stock Option | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 75,000 | 0 | - | - | Stock Option | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. | 02 Feb 2021 | 75,000 | 608,693 (0%) | 0% | 8.8 | 660,000 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. | 02 Feb 2021 | 75,000 | 533,693 (0%) | 0% | 8.8 | 660,000 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.58 per share. | 02 Feb 2021 | 58,137 | 458,693 (0%) | 0% | 20.6 | 1,196,459 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.84 per share. | 02 Feb 2021 | 9,900 | 459,293 (0%) | 0% | 20.8 | 206,316 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 21.59 per share. | 02 Feb 2021 | 600 | 458,693 (0%) | 0% | 21.6 | 12,954 | Common Stock |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2020 | 190,650 | 190,650 | - | - | Stock Option | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2020 | 106,650 | 458,693 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Howard W. Robin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 16.93 per share. | 16 Nov 2020 | 11,975 | 352,043 (0%) | 0% | 16.9 | 202,737 | Common Stock |